Oxurion completes enrollment in plasma kallikrein inhibitor trial

Oxurion NV has completed enrollment in a phase 1 study of its plasma kallikrein inhibitor for treatment of diabetic macular edema, according to a press release.

The safety of a single intravitreal injection of THR-149 will be evaluated in 15 patients with visual impairment due to center-involved DME. Three ascending dose levels will be used.

“We are delighted to have completed patient recruitment in this important clinical trial earlier than anticipated,” Oxurion CEO Patrik De Haes, MD, said. “This study has been designed to assess THR-149's safety profile and to provide the information needed to plan the future clinical development plan of this novel plasma kallikrein inhibitor for the treatment of DME.”

 

Oxurion NV has completed enrollment in a phase 1 study of its plasma kallikrein inhibitor for treatment of diabetic macular edema, according to a press release.

The safety of a single intravitreal injection of THR-149 will be evaluated in 15 patients with visual impairment due to center-involved DME. Three ascending dose levels will be used.

“We are delighted to have completed patient recruitment in this important clinical trial earlier than anticipated,” Oxurion CEO Patrik De Haes, MD, said. “This study has been designed to assess THR-149's safety profile and to provide the information needed to plan the future clinical development plan of this novel plasma kallikrein inhibitor for the treatment of DME.”